Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irpagratinib + atezolizumab + bevacizumab
- Development stage
- Unknown
- Lead developer
- Abbisko Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ABSK-011 + atezolizumab + bevacizumab is an investigational triplet combination therapy being developed for the treatment of advanced or unresectable hepatocellular carcinoma (HCC), specifically in patients with FGF19 overexpression. The regimen consists of **irpagratinib** (ABSK-011), a highly selective small-molecule inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4); **atezolizumab**, a monoclonal antibody targeting Programmed Death-Ligand 1 (PD-L1); and **bevacizumab**, a monoclonal antibody targeting Vascular Endothelial Growth Factor (VEGF). By targeting the FGF19-FGFR4 signaling axis, which is a key driver in a subset of HCC, alongside immune checkpoint inhibition and anti-angiogenesis, the triplet aims to provide a synergistic therapeutic effect. The combination is currently being evaluated in Phase 2 clinical trials (NCT05441475).
- Other names
- irpagratinib + atezolizumab + bevacizumab
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on irpagratinib + atezolizumab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irpagratinib + atezolizumab + bevacizumab.